Bittner S, Wiendl H
Neurotherapeutics. 2015; 13(1):4-19.
PMID: 26563391
PMC: 4720668.
DOI: 10.1007/s13311-015-0405-3.
Gonatas N, Greene M, Waksman B
Immunol Today. 2014; 7(5):121-6.
PMID: 25289996
PMC: 7133909.
DOI: 10.1016/0167-5699(86)90072-1.
Rolstad B
Front Immunol. 2014; 5:283.
PMID: 24982659
PMC: 4058755.
DOI: 10.3389/fimmu.2014.00283.
OBrien K, Gran B, Rostami A
Immunotherapy. 2010; 2(1):99-115.
PMID: 20231863
PMC: 2837464.
DOI: 10.2217/imt.09.61.
Zhang H, Podojil J, Luo X, Miller S
J Immunol. 2008; 181(7):4638-47.
PMID: 18802066
PMC: 2853378.
DOI: 10.4049/jimmunol.181.7.4638.
Multi-peptide coupled-cell tolerance ameliorates ongoing relapsing EAE associated with multiple pathogenic autoreactivities.
Smith C, Miller S
J Autoimmun. 2007; 27(4):218-31.
PMID: 17289470
PMC: 1868454.
DOI: 10.1016/j.jaut.2006.12.002.
Antigenized antibodies expressing Vbeta8.2 TCR peptides immunize against rat experimental allergic encephalomyelitis.
Musselli C, Daverio-Zanetti S, Zanetti M
J Immune Based Ther Vaccines. 2004; 2(1):9.
PMID: 15541175
PMC: 539290.
DOI: 10.1186/1476-8518-2-9.
Monoclonal antibody therapy in experimental allergic encephalomyelitis and multiple sclerosis.
Zhang X, Hupperts R, De Baets M
Immunol Res. 2003; 28(1):61-78.
PMID: 12947225
DOI: 10.1385/IR:28:1:61.
Optic neuritis, a new variant of experimental encephalomyelitis, a durable model for all seasons, now in its seventieth year.
Steinman L
J Exp Med. 2003; 197(9):1065-71.
PMID: 12732653
PMC: 2193965.
DOI: 10.1084/jem.20030320.
Myelin-specific CD8 T cells in the pathogenesis of experimental allergic encephalitis and multiple sclerosis.
Steinman L
J Exp Med. 2001; 194(5):F27-30.
PMID: 11535639
PMC: 2195937.
DOI: 10.1084/jem.194.5.f27.
Autopathogenic T helper cell type 1 (Th1) and protective Th2 clones differ in their recognition of the autoantigenic peptide of myelin proteolipid protein.
Das M, Nicholson L, Greer J, Kuchroo V
J Exp Med. 1997; 186(6):867-76.
PMID: 9294141
PMC: 2199041.
DOI: 10.1084/jem.186.6.867.
Experimental immunotherapies for multiple sclerosis.
Martin R, McFarland H
Springer Semin Immunopathol. 1996; 18(1):1-24.
PMID: 8984675
PMC: 7087544.
DOI: 10.1007/BF00792605.
In vivo treatment with a monoclonal chimeric anti-CD4 antibody results in prolonged depletion of circulating CD4+ cells in chimpanzees.
Jonker M, Slingerland W, Treacy G, van Eerd P, Pak K, Wilson E
Clin Exp Immunol. 1993; 93(3):301-7.
PMID: 8103714
PMC: 1554916.
DOI: 10.1111/j.1365-2249.1993.tb08176.x.
Inhibition of murine nephritogenic effector T cells by a clone-specific suppressor factor.
Meyers C, Kelly C
J Clin Invest. 1994; 94(5):2093-104.
PMID: 7962556
PMC: 294651.
DOI: 10.1172/JCI117564.
Anti-class II MHC antibodies prevent and treat EAE without APC depletion.
Smith R, Morgan A, Wraith D
Immunology. 1994; 83(1):1-8.
PMID: 7821954
PMC: 1415013.
Activation of CD4+ T cells in the presence of a nondepleting monoclonal antibody to CD4 induces a Th2-type response in vitro.
Stumbles P, Mason D
J Exp Med. 1995; 182(1):5-13.
PMID: 7790823
PMC: 2192090.
DOI: 10.1084/jem.182.1.5.
Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation.
Karussis D, Lehmann D, Ovadia H, Mizrachi-Koll R, Ben-Nun A, Abramsky O
J Clin Invest. 1993; 92(2):765-72.
PMID: 7688762
PMC: 294912.
DOI: 10.1172/JCI116648.
Peptide determinants of myelin proteolipid protein (PLP) in autoimmune demyelinating disease: a review.
Tuohy V
Neurochem Res. 1994; 19(8):935-44.
PMID: 7528355
DOI: 10.1007/BF00968703.
Immunomodulator therapy in inflammatory bowel disease.
Choi P, Targan S
Dig Dis Sci. 1994; 39(9):1885-92.
PMID: 7521821
DOI: 10.1007/BF02088121.
Successful prevention and treatment of autoimmune encephalomyelitis by short-term administration of anti-T-cell receptor alpha beta antibody.
Matsumoto Y, Tsuchida M, Hanawa H, Abo T
Immunology. 1994; 81(1):1-7.
PMID: 7510661
PMC: 1422289.